June Chih Liu, MD
Neurology · Arcadia, CANPI 1891768479
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 40.6% of the total. Reporting peaked in 2022 at $12,612 and has fallen 68.4% since, to $3,989 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 778 payments — averaging $52.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$17K
- Amgen$2K
- AbbVie$1K
- Kyowa Kirin, Inc.$1K
- Medtronic$1K
- MDD US Operations, LLC$1K
- plus $17K from 50 others
What the payments were for
- Speaking & faculty fees$15,79339%
- Travel & lodging$6482%
- Food & beverage$24,18359%
- Education$3481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,972 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 135 | $807,181 |
| RytaryCarbidopa/Levodopa | 267 | $344,276 |
| AustedoDeutetrabenazine | 12 | $181,209 |
| NeuproRotigotine | 134 | $146,226 |
| XadagoSafinamide Mesylate | 67 | $90,212 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 32 | $86,543 |
| JardianceEmpagliflozin | 86 | $68,939 |
| NourianzIstradefylline | 19 | $65,062 |
| Repatha SureclickEvolocumab | 94 | $64,275 |
| VascepaIcosapent Ethyl | 106 | $55,529 |
| Nurtec OdtRimegepant Sulfate | 24 | $51,931 |
| Rasagiline Mesylate | 112 | $25,680 |
| OngentysOpicapone | 18 | $17,787 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $16,968 |
| FarxigaDapagliflozin Propanediol | 25 | $15,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,051 | $807,181135 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $754 | $347,004339 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $16,633 | $181,20912 claims |
| UCB, Inc.Neupro | $681 | $146,226134 claims |
| Grifols USA, LLCGamunex-C | $448 | $86,54332 claims |
| Kyowa Kirin, Inc.Nourianz | $1,358 | $65,06219 claims |
| PfizerNurtec Odt | $653 | $51,93124 claims |
| Neurocrine Biosciences, Inc.Ongentys | $1,123 | $17,78718 claims |
| AbbVieNamzaric | $1,476 | $16,96811 claims |
| AstraZenecaFarxiga | $996 | $15,11625 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $16 | $5,47116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Arcadia
- Rami ApelianArcadia$479K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.